BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Blatt J, Morrell DS, Buck S, Zdanski C, Gold S, Stavas J, Powell C, Burkhart CN. β-Blockers for Infantile Hemangiomas: A Single-Institution Experience. Clin Pediatr (Phila) 2011;50:757-63. [DOI: 10.1177/0009922811405517] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Painter SL, Hildebrand GD. Review of topical beta blockers as treatment for infantile hemangiomas. Survey of Ophthalmology 2016;61:51-8. [DOI: 10.1016/j.survophthal.2015.08.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
2 Mcmahon P, Oza V, Frieden IJ. Topical Timolol for Infantile Hemangiomas: Putting a Note of Caution in “Cautiously Optimistic”: Commentary. Pediatric Dermatology 2012;29:127-30. [DOI: 10.1111/j.1525-1470.2011.01685.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 5.0] [Reference Citation Analysis]
3 Frommelt P, Juern A, Siegel D, Holland K, Seefeldt M, Yu J, Uhing M, Wade K, Drolet B. Adverse Events in Young and Preterm Infants Receiving Topical Timolol for Infantile Hemangioma. Pediatr Dermatol 2016;33:405-14. [DOI: 10.1111/pde.12869] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 6.7] [Reference Citation Analysis]
4 MacIsaac ZM, Nayar HS, Gehris R, Mehta D, Geisler S, Grunwaldt LJ. Treatment for Infantile Hemangiomas: Selection Criteria, Safety, and Outcomes Using Oral Propranolol During the Early Phase of Propranolol Use for Hemangiomas. J Craniofac Surg 2016;27:159-62. [PMID: 26674892 DOI: 10.1097/SCS.0000000000002206] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
5 Park YW, Yeom KB, Choi JW, Kim DY, Shin H, Kim KH. Effect of propranolol on the treatment of infantile hemangiomas: a single tertiary center 3-year experience. J Dermatolog Treat 2014;25:391-5. [PMID: 23273264 DOI: 10.3109/09546634.2012.761667] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Abu Ata N, Meyers AB, Merrow AC. Imaging of Vascular Anomalies in the Pediatric Musculoskeletal System. Semin Roentgenol 2021;56:288-306. [PMID: 34281681 DOI: 10.1053/j.ro.2021.05.004] [Reference Citation Analysis]
7 Painter SL, Hildebrand GD. Topical timolol maleate 0.5% solution for the management of deep periocular infantile hemangiomas. J AAPOS 2016;20:172-174.e1. [PMID: 27079600 DOI: 10.1016/j.jaapos.2015.11.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Sharma VK, Fraulin FO, Dumestre DO, Walker L, Harrop AR. Beta-blockers for the treatment of problematic hemangiomas. Can J Plast Surg 2013;21:23-8. [PMID: 24431932 DOI: 10.1177/229255031302100103] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
9 Ovadia SA, Landy DC, Cohen ER, Yang EY, Thaller SR. Local Administration of β-Blockers for Infantile Hemangiomas: A Systematic Review and Meta-analysis. Annals of Plastic Surgery 2015;74:256-62. [DOI: 10.1097/sap.0000000000000390] [Cited by in Crossref: 31] [Cited by in F6Publishing: 4] [Article Influence: 4.4] [Reference Citation Analysis]
10 Jian D, Chen X, Babajee K, Su J, Li J, Hu X, Xie H, Li J. Adverse effects of propranolol treatment for infantile hemangiomas in China. Journal of Dermatological Treatment 2013;25:388-90. [DOI: 10.3109/09546634.2012.755249] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
11 Marqueling AL, Oza V, Frieden IJ, Puttgen KB. Propranolol and Infantile Hemangiomas Four Years Later: A Systematic Review. Pediatr Dermatol 2013;30:182-91. [DOI: 10.1111/pde.12089] [Cited by in Crossref: 151] [Cited by in F6Publishing: 117] [Article Influence: 16.8] [Reference Citation Analysis]
12 Berk DR, Lehman PA, Franz TJ, Blunt JR, Bayliss SJ. On Topical Timolol Gel-Forming Solution for Infantile Hemangiomas. Pediatric Dermatology 2013;30:160-1. [DOI: 10.1111/pde.12060] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
13 Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, Chun RH, Garzon MC, Holland KE, Liberman L. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131:128-140. [PMID: 23266923 DOI: 10.1542/peds.2012-1691] [Cited by in Crossref: 304] [Cited by in F6Publishing: 219] [Article Influence: 30.4] [Reference Citation Analysis]
14 Mimura H, Akita S, Fujino A, Jinnin M, Ozaki M, Osuga K, Nakaoka H, Morii E, Kuramochi A, Aoki Y, Arai Y, Aramaki N, Inoue M, Iwashina Y, Iwanaka T, Ueno S, Umezawa A, Ozeki M, Ochi J, Kinoshita Y, Kurita M, Seike S, Takakura N, Takahashi M, Tachibana T, Chuman K, Nagata S, Narushima M, Niimi Y, Nosaka S, Nozaki T, Hashimoto K, Hayashi A, Hirakawa S, Fujikawa A, Hori Y, Matsuoka K, Mori H, Yamamoto Y, Yuzuriha S, Rikihisa N, Watanabe S, Watanabe S, Kuroda T, Sugawara S, Ishikawa K, Sasaki S. Japanese clinical practice guidelines for vascular anomalies 2017. Jpn J Radiol 2020;38:287-342. [PMID: 32207066 DOI: 10.1007/s11604-019-00885-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
15 Mimura H, Akita S, Fujino A, Jinnin M, Ozaki M, Osuga K, Nakaoka H, Morii E, Kuramochi A, Aoki Y, Arai Y, Aramaki N, Inoue M, Iwashina Y, Iwanaka T, Ueno S, Umezawa A, Ozeki M, Ochi J, Kinoshita Y, Kurita M, Seike S, Takakura N, Takahashi M, Tachibana T, Chuman K, Nagata S, Narushima M, Niimi Y, Nosaka S, Nozaki T, Hashimoto K, Hayashi A, Hirakawa S, Fujikawa A, Hori Y, Matsuoka K, Mori H, Yamamoto Y, Yuzuriha S, Rikihisa N, Watanabe S, Watanabe S, Kuroda T, Sugawara S, Ishikawa K, Sasaki S. Japanese clinical practice guidelines for vascular anomalies 2017. Pediatr Int 2020;62:257-304. [PMID: 32202048 DOI: 10.1111/ped.14077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Blatt J, Mclean TW, Castellino SM, Burkhart CN. A review of contemporary options for medical management of hemangiomas, other vascular tumors, and vascular malformations. Pharmacology & Therapeutics 2013;139:327-33. [DOI: 10.1016/j.pharmthera.2013.05.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
17 Gunturi N, Ramgopal S, Balagopal S, Scott JX. Propranolol therapy for infantile hemangioma. Indian Pediatr 2013;50:307-13. [PMID: 23680605 DOI: 10.1007/s13312-013-0098-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
18 Semkova K, Kazandjieva J. Topical timolol maleate for treatment of infantile haemangiomas: preliminary results of a prospective study: Topical timolol for treatment of infantile haemangiomas. Clinical and Experimental Dermatology 2013;38:143-6. [DOI: 10.1111/j.1365-2230.2012.04425.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
19 Sarkar R, Sethi S, Garg VK. Topical timolol in nasal tip hemangioma: a viable alternative to systemic therapy. Int J Dermatol 2015;54:e239-41. [PMID: 26010405 DOI: 10.1111/ijd.12807] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
20 Semkova K, Kazandjieva J. Rapid complete regression of an early infantile hemangioma with topical timolol gel: Regression of an IH with timolol. Int J Dermatol 2014;53:241-2. [DOI: 10.1111/j.1365-4632.2011.05441.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
21 Zhang Q, Chantasart D, Kevin Li S. Evaluation of β-blocker Gel and Effect of Dosing Volume for Topical Delivery. Journal of Pharmaceutical Sciences 2015;104:1721-31. [DOI: 10.1002/jps.24390] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
22 Satterfield KR, Chambers CB. Current Treatment and Management of Infantile Hemangiomas. Surv Ophthalmol. 2019; Epub ahead of print. [PMID: 30772366 DOI: 10.1016/j.survophthal.2019.02.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
23 Blei F. Medical and Genetic Aspects of Vascular Anomalies. Techniques in Vascular and Interventional Radiology 2013;16:2-11. [DOI: 10.1053/j.tvir.2013.01.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
24 Merino-bohórquez V, Casas M, Caracuel F, Cameán M, Fernández-anguita MJ, Ramírez-soto G, Lucero MJ. Physicochemical stability of a new topical timolol 0.5% gel formulation for the treatment of infant hemangioma. Pharmaceutical Development and Technology 2014;20:562-9. [DOI: 10.3109/10837450.2014.898657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
25 Goelz R, Poets CF. Incidence and treatment of infantile haemangioma in preterm infants. Arch Dis Child Fetal Neonatal Ed 2015;100:F85-91. [PMID: 25352093 DOI: 10.1136/archdischild-2014-306197] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
26 Tan X, Guo S, Wang C. Propranolol in the Treatment of Infantile Hemangiomas. Clin Cosmet Investig Dermatol 2021;14:1155-63. [PMID: 34511960 DOI: 10.2147/CCID.S332625] [Reference Citation Analysis]
27 Phillips RJ, Lokmic Z, Crock CM, Penington A. Infantile haemangiomas that failed treatment with propranolol: Clinical and histopathological features: Haemangiomas unresponsive to propranolol. J Paediatr Child Health 2014;50:619-25. [DOI: 10.1111/jpc.12600] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
28 Mimura H, Akita S, Fujino A, Jinnin M, Ozaki M, Osuga K, Nakaoka H, Morii E, Kuramochi A, Aoki Y, Arai Y, Aramaki N, Inoue M, Iwashina Y, Iwanaka T, Ueno S, Umezawa A, Ozeki M, Ochi J, Kinoshita Y, Kurita M, Seike S, Takakura N, Takahashi M, Tachibana T, Chuman K, Nagata S, Narushima M, Niimi Y, Nosaka S, Nozaki T, Hashimoto K, Hayashi A, Hirakawa S, Fujikawa A, Hori Y, Matsuoka K, Mori H, Yamamoto Y, Yuzuriha S, Rikihisa N, Watanabe S, Watanabe S, Kuroda T, Sugawara S, Ishikawa K, Sasaki S. Japanese Clinical Practice Guidelines for Vascular Anomalies 2017. J Dermatol 2020;47:e138-83. [PMID: 32200557 DOI: 10.1111/1346-8138.15189] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Blei F, McElhinney DB, Guarini A, Presti S. Cardiac screening in infants with infantile hemangiomas before propranolol treatment. Pediatr Dermatol. 2014;31:465-470. [PMID: 24889812 DOI: 10.1111/pde.12344] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
30 Semkova K, Marina S, Kazandjieva J. Topical Treatment of Infantile Hemangiomas – Where Are We Now? / Topikalni tretman infantilnih hemangioma – gde smo danas? Serbian Journal of Dermatology and Venerology 2011;3:145-52. [DOI: 10.2478/v10249-011-0046-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
31 Ryan J. Propranolol Use for Infantile Hemangiomas. Plast Surg Nurs 2015;35:129-30. [PMID: 26313676 DOI: 10.1097/PSN.0000000000000105] [Reference Citation Analysis]
32 Gummi R, Stahl ED, Marsh JD. Topical timolol for an iris hemangioma. J AAPOS 2018;22:156-8. [PMID: 29412149 DOI: 10.1016/j.jaapos.2017.10.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]